Spleen tyrosine kinase inhibition in the treatment of autoimmune, allergic and autoinflammatory diseases

Arthritis Research and Therapy

Volumn 12, Issue 6, 2010, Pages

  Pamuk, Omer N ^a,b   Tsokos, George C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b TRAKYA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT FACTOR I; FOSTAMATINIB; INTERLEUKIN 6; METALLOPROTEINASE; METHOTREXATE; PADGEM PROTEIN; PLACEBO; PROTEIN KINASE SYK; PROTEIN KINASE ZAP 70; PROTEIN SH2; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; SIGNAL PEPTIDE;

ALLERGIC RHINITIS; AMINO TERMINAL SEQUENCE; AUTOIMMUNE DISEASE; AUTOINFLAMMATORY DISEASE; CYTOPENIA; DIARRHEA; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE SYSTEM; OSTEOBLAST; OSTEOCLAST; PROTEIN INTERACTION; REVIEW; RHEUMATOID ARTHRITIS; SYNOVIOCYTE; SYSTEMIC LUPUS ERYTHEMATOSUS; TISSUE INJURY; CLINICAL TRIAL (TOPIC); DRUG ANTAGONISM; ENZYMOLOGY; HYPERSENSITIVITY; INFLAMMATION;

AUTOIMMUNE DISEASES; CLINICAL TRIALS AS TOPIC; HUMANS; HYPERSENSITIVITY; INFLAMMATION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES;

EID: 79959261430     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3198     Document Type: Review

References (64)

1. Zhu Y, Herlaar E, Masuda ES, Burleson GR, Nelson AJ, Grossbard EB, Clemens GR. Immunotoxicity assessment for the novel Spleen tyrosine kinase inhibitor R406. Toxicol Appl Pharmacol 2007, 221:268-277. 10.1016/j.taap.2007.03.027, 17445852.
2. Wong BR, Grossbard EB, Payan DG, Masuda E. Targeting Syk as a treatment for allergic and autoimmune diseases. Expert Opin Investig Drugs 2004, 13:743-762. 10.1517/13543784.13.7.743, 15212616.
3. Tohyama Y, Yamamura H. Protein tyrosine kinase, Syk: a key player in phagocytic cells. J Biochem 2009, 145:267-273. 10.1093/jb/mvp001, 19124456.
4. Mocsai A, Ruland J, Tybulewicz LJ. The Syk tyrosine kinase: a crucial player in diverse biological functions. Nat Rev Immunol 2010, 10:387-402. 20467426, 10.1038/nri2765.
5. Sadak K, Takano T, Yanagi S, Yamamura H. Structure and function of Syk protein-tyrosine kinase. J Biochem 2001, 130:177-186.
6. Berton G, Mocsai A, Lowell A. Src and Syk kinases: key regulators of phagocytic cell activation. Trends Immunol 2005, 26:208-214. 15797511, 10.1016/j.it.2005.02.002.
7. Crowley MT, Costello PS, Fitzer-Attas CJ, Turner M, Meng F, Lowell CA, Tybulewicz VL, DeFranco AL. A critical role for Syk in signal transduction and phagocytosis mediated by Fcgamma receptors on macrophages. J Exp Med 1997, 186:1027-1039. 2199061, 9314552, 10.1084/jem.186.7.1027.
8. Turner M, Schweighoffer E, Colucci F, Di Santo JP, Tybulewicz VL. Tyrosine kinase Syk: essential functions for immunoreceptor signalling. Immunol Today 2000, 21:148-154. 10.1016/S0167-5699(99)01574-1, 10689303.
9. Turner M, Mee PJ, Costello PS, Williams O, Price AA, Duddy LP, Furlong MT, Geahlen RL, Tybulewicz VL. Perinatal lethality and blocked B-cell development in mice lacking the tyrosine kinase Syk. Nature 1995, 378:298-302. 10.1038/378298a0, 7477352.
10. Elder ME, Lin D, Clever J, Chan AC, Hope TJ, Weiss A, Parslow TG. Human severe combined immunodeficiency due to a defect in ZAP-70, a T cell tyrosine kinase. Science 1994, 264:1596-1599. 10.1126/science.8202712, 8202713.
11. Schweighoffer E, Vanes L, Mathiot A, Nakamura T, Tybulewicz VL. Unexpected requirement for ZAP-70 in pre-B cell development and allelic exclusion. Immunity 2003, 18:523-533. 10.1016/S1074-7613(03)00082-7, 12705855.
12. Palacios EH, Weiss A. Distinct roles for Syk and ZAP-70 during early thymocyte development. J Exp Med 2007, 204:1703-1715. 2118636, 17606633, 10.1084/jem.20070405.
13. Kurosaki T, Hikida M. Tyrosine kinases and their substrates in B lymphocytes. Immunol Rev 2009, 228:132-148. 10.1111/j.1600-065X.2008.00748.x, 19290925.
14. Hong JJ, Yankee TM, Harrison ML, Geahlen RL. Regulation of signaling in B cells through the phosphorylation of Syk on linker region tyrosines. A mechanism for negative signaling by the Lyn tyrosine kinase. J Biol Chem 2002, 277:31703-31714. 10.1074/jbc.M201362200, 12077122.
15. Ghosh D, Tsokos GC. Spleen tyrosine kinase: an Src family of non-receptor kinase has multiple functions and represents a valuable therapeutic target in the treatment of autoimmune and inflammatory diseases. Autoimmunity 2010, 43:48-55. 10.3109/08916930903374717, 20001666.
16. Kiefer F, Brumell J, Al-Alawi N, Latour S, Cheng A, Veillette A, Grinstein S, Pawson T. The Syk protein kynase is essential for cgamma receptor signaling in macrophages and neutrophils. Mol Cell Biol 1998, 18:4209-4220. 109005, 9632805.
17. Tohyama Y, Yamamura H. Complement-mediated phagocytosis - The role of Syk. IUBMB Life 2006, 58:304-308. 10.1080/15216540600746377, 16754322.
18. Shi Y, Tohyama Y, Kadono T, He J, Miah SM, Hazama R, Tanaka C, Tohyama K, Yamamura H. Protein-tyrosine kinase, Syk is required for pathogen engulfment in complement-mediated phagocytosis. Blood 2006, 107:4554-4562. 10.1182/blood-2005-09-3616, 16449524.
19. Luskova P, Draber P. Modulation of the Fcepsilon receptor I signaling by tyrosine kinase inhibitors: search for therapeutic targets of inflammatory and allergy diseases. Curr Pharm Des 2004, 10:1727-1737. 10.2174/1381612043384538, 15180535.
20. Matsubara S, Li G, Takeda K, Loader JE, Pine P, Masuda ES, Miyahara N, Miyahara S, Lucas JJ, Dakhama A, Gelfand EW. Inhibition of spleen tyrosine kinase prevents mast cell activation and airway hyperresponsiveness. Am J Respir Crit Care Med 2006, 173:56-63. 16192454, 10.1164/rccm.200503-361OC, 2662982.
21. Costello PS, Turner M, Walters AE, Cunningham CN, Bauer PH, Downward J, Tybulewicz VL. Critical role for the tyrosine kinase Syk in signaling through the high affinity IgE receptor of mast cells. Oncogene 1996, 13:2595-2605.
22. Matsubara S, Koya T, Takeda K, Joetham A, Miyahara N, Pine P, Masuda ES, Swasey CH, Gelfand EW. Syk activation in dendritic cells is essential for airway hyperresponsiveness and inflammation. Am J Respir Cell Mol Biol 2006, 34:426-433. 2644204, 16339999, 10.1165/rcmb.2005-0298OC.
23. Masuda ES, Schmitz J. Syk inhibitors as treatment for allergic diseases. Pulm Pharmacol Ther 2008, 21:461-467. 17669674, 10.1016/j.pupt.2007.06.002.
24. Poole A, Gibbins JM, Turner M, van Vugt MJ, van de Winkel JG, Saito T, Tybulewicz VL, Watson SP. The Fc receptor γ-chain and the tyrosine kinase Syk are essential for activation of mouse platelets by collagen. EMBO J 1997, 16:2333-2341. 1169834, 9171347, 10.1093/emboj/16.9.2333.
25. Ozaki Y, Suzuki-Inoue K, Inoue O. Novel interactions in platelet biology: CLEC2/podoplanin and laminin/GPVI. J Thromb Haemost 2009, 7(Suppl 1):191-194. 10.1111/j.1538-7836.2009.03372.x, 19630798.
26. Boylan B, Gao C, Rathore V, Gill JC, Newman DK, Newman PJ. Identification of FcγRIIa as the ITAM-bearing receptor mediating αIIbβ3 outside-in integrin signaling in human platelets. Blood 2008, 112:2780-2786. 2556613, 18641368, 10.1182/blood-2008-02-142125.
27. Zou W, Kitaura H, Reeve J, Long F, Tybulewicz VL, Shattil SJ, Ginsberg MH, Ross FP, Teitelbaum SL. Syk, c-Src, the αIIbβ3 outside-in integrin signaling in human platelets. J Cell Biol 2007, 176:877-888. 2064061, 17353363, 10.1083/jcb.200611083.
28. Suzuki-Inoue K, Fuller GL, García A, Eble JA, Pöhlmann S, Inoue O, Gartner TK, Hughan SC, Pearce AC, Laing GD, Theakston RD, Schweighoffer E, Zitzmann N, Morita T, Tybulewicz VL, Ozaki Y, Watson SP. A novel syk-dependent mechanism of platelet activation by the C-type lectin receptor CLEC-2. Blood 2006, 107:542-549. 10.1182/blood-2005-05-1994, 16174766.
29. Abhatian F, Guerriero A, Sebzda E, Lu MM, Zhou R, Mocsai A, Myers EE, Huang B, Jackson DG, Ferrari VA, Tybulewicz V, Lowell CA, Lepore JJ, Koretzky GA, Kahn ML. Regulation of blood and lymphatic vascular separation by signaling proteins SLP-76 and Syk. Science 2003, 299:247-251. 2982679, 12522250, 10.1126/science.1079477.
30. Mocsai A, Humphrey MB, Van Zieffle JA, Hu Y, Burghardt A, Spusta SC, Majumdar S, Lanier LL, Lowell CA, Nakamura MC. The immunomodulatory adapter proteins DAP12 and Fc receptor gamma chain (FcRgamma) regulate development of functional osteoclasts through the Syk tyrosine kinase. Proc Natl Acad Sci USA 2004, 101:6158-6163. 395939, 15073337, 10.1073/pnas.0401602101.
31. Koga T, Inui M, Inoue K, Kim S, Suematsu A, Kobayashi E, Iwata T, Ohnishi H, Matozaki T, Kodama T, Taniguchi T, Takayanagi H, Takai T. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homestasis. Nature 2004, 428:758-763. 10.1038/nature02444, 15085135.
32. Humphrey BT, Lanier LL, Nakamura MC. Role of ITAM-containing adapter proteins and their receptors in the immune system and bone. Immunol Rev 2005, 208:50-65. 10.1111/j.0105-2896.2005.00325.x, 16313340.
33. Cha HS, Boyle DL, Inoue T, Schoot R, Tak PP. A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes. J Pharmacol Exp Ther 2006, 317:571-578. 10.1124/jpet.105.097436, 16452391.
34. Mun SH, Kim JW, Nah SS, Ko NY, Lee JH, Kim JD, Kim do K, Kim HS, Choi JD, Kim SH, Lee CK, Park SH, Kim BK, Kim HS, Kim YM, Choi WS. Tumor necrosis factor alpha-induced interleukin-32 is positively regulated via the Syk/protein kinase Cdelta/JNK pathway in rheumatoid synovial fibroblasts. Arthritis Rheum 2009, 60:678-685. 10.1002/art.24299, 19248119.
35. Kyttaris V, Tsokos GC. Syk kinase as a treatment target for therapy in autoimmune diseases. Clin Immunol 2007, 124:235-237. 1986716, 17662659, 10.1016/j.clim.2007.06.005.
36. Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, Schaefer-Cutillo J, De Vos S, Sinha R, Leonard JP, Cripe LD, Gregory SA, Sterba MP, Lowe AM, Levy R, Shipp MA. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010, 115:2578-2585. 10.1182/blood-2009-08-236471, 19965662.
37. Braselmann S, Taylor V, Zhao H, Wang S, Sylvian C, Baloum M, Qu K, Herlaar E, Lau A, Young C, Wong BR, Lowell S, Sun T, Park G, Argade A, Jurcevic S, Pine P, Singh R, Grossbard EB, Payan DG, Masuda ES. R406, an orally available spleen tyrosine kinase inhibitor blocks Fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther 2006, 319:998-1008. 10.1124/jpet.106.109058, 16946104.
38. Pine PR, Chang B, Schoettler N, Banquerigo ML, Wang S, Lau A, Zhao F, Grossbard EB, Payan DG, Brahn E. Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor. Clin Immunol 2007, 124:244-257. 10.1016/j.clim.2007.03.543, 17537677.
39. Meltzer EO, Berkowitz RB, Grossbard EB. An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment. J Allergy Clin Immunol 2005, 115:791-796. 10.1016/j.jaci.2005.01.040, 15806000.
40. Seow CJ, Chue SC, Wong WSF. Piceatannol, A Syk-selective tyrosine kinase inhibitor, attenuated antigen challenge of guinea pig airways in vitro. Eur J Pharmacol 2002, 443:189-196. 10.1016/S0014-2999(02)01534-0, 12044809.
41. Yamamoto N, Takeshita K, Shicjijo M, Kokubo T, Sato M, Nakashima K, Ishimori M, Nagai H, Li YF, Yura T, Bacon KB. The orally available spleen tyrosine kinase inhibitor 2-[7-(3,4-Dimethhoxyphenyl)-imidazo [1,2-c]pyrimidin-5-ylamino] nicotinamide Dihydrochloride (BAY 61-3606) blocks antigen-induced airway inflammation in rodents. J Pharmacol Exp Ther 2003, 306:1174-1181. 10.1124/jpet.103.052316, 12766258.
42. Jakus Z, Simon E, Balazs B, Mocsai A. Genetic deficiency of Syk protects mice from autoantibody-induced arthritis. Arthritis Rheum 2010, 62:1899-1910. 2972644, 20201079.
43. Schymeinsky J, Sindrilaru A, Frommhold D, Sperandio M, Gerstl R, Then C, Mócsai A, Scharffetter-Kochanek K, Walzog B. The Vav binding site of the non-receptor tyrosine kinase Syk at Tyr 348 is critical for β2 integrin (CD11/CD18)-mediated neutrophil migration. Blood 2006, 108:3919-3927. 10.1182/blood-2005-12-030387, 16882714.
44. Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol 2001, 19:275-290. 10.1146/annurev.immunol.19.1.275, 11244038.
45. Grossbard E, Baluom M, Kivitz AJ. A phase I randomized, double-blind, placebo-controlled, pharmacokinetic study of R788/406 and methotrexate in sixteen patients with rheumatoid arthritis. Arthritis Rheum 2006, 54(Suppl 9):S408.
46. Weinblatt ME, Kavanaugh A, Burgos-Vagas R, Dikranian AH, Medrano-Ramirez G, Morales-Torres JL, Murphy FT, Musser TK, Straniero N, Grossbard E. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum 2008, 58:3309-3318. 10.1002/art.23992, 18975322.
47. Weinblatt ME, Kavanaugh A, Genovese M, Grossbard E, Magilavy D. Treatment of rheumatoid arthritis (RA) with an oral Syk kinase inhibitor: a 6 month randomized placebo controlled phase 2b study in patients with active RA on chronic methotrexate (abstract). N Engl J Med 2010, 363:1303-1312. 10.1056/NEJMoa1000500, 20879880.
48. Genovese M, Kavanaugh A, Peterfy C, Magilavy D. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis (RA): a 3 month randomized placebo controlled phase 2 study in patients with active RA who had failed biologic agents (abstract). Arthritis Rheum 2009, 60(Suppl):469.
49. Enyedy EJ, Nambiar MP, Liossis SN, Dennis G, Kammer GM, Tsokos GC. Fc epsilon receptor type I gamma chain replaces the deficient T cell receptor zeta chain in T cells of patients with systemic lupus erythematosus. Arthritis Rheum 2001, 44:1114-1121. 10.1002/1529-0131(200105)44:5<1114::AID-ANR192>3.0.CO;2-B, 11352243.
50. Bahjat FR, Pine PR, Reitsma A, Cassafer G, Baluom M, Grillo S, Chang B, Zhao FF, Payan DG, Grossbard EB, Daikh DI. An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus. Arthritis Rheum 2008, 58:1433-1444. 10.1002/art.23428, 18438845.
51. Smith J, McDaid JP, Bhangal G, Chawanasuntorapoj R, Masuda ES, Cook HT, Pusey CD, Tam FWK. A spleen tyrosine kinase inhibitor reduces the severity of established glomerulonephritis. J Am Soc Nephrol 2010, 21:231-236. 10.1681/ASN.2009030263, 19959716.
52. Deng GM, Liu L, Bahjat R, Pine PR, Tsokos GC. Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice. Arthritis Rheum 2010, 62:2086-2092. 2902591, 20222110, 10.1002/art.27534.
53. Plaut M, Valentine MD. Clinical practice. Allergic rhinitis. N Engl J Med 2005, 353:1934-1944. 10.1056/NEJMcp044141, 16267324.
54. Guyer BJ, Shimamoto SR, Bradhurst AL, Grossbard EB, Dreskin SC, Nelson HS. Mast cell inhibitor R112 is well tolerated and affects prostaglandin D2 but not other mediators, symptoms, or nasal volumes in a nasal challenge model of allergic rhinitis. Allergy Asthma Proc 2006, 27:208-213. 10.2500/aap.2006.27.2861, 16913263.
55. Cines DB, Blanchette VS. Immune thrombocytopeic purpura. N Engl J Med 2002, 346:995-1008. 10.1056/NEJMra010501, 11919310.
56. Podolanczuk A, Lazarus AH, Crow AR, Grossbard E, Bussel JB. Of mice and men: an open -label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood 2009, 113:3154-3160. 10.1182/blood-2008-07-166439, 19096013.
57. Pamuk ON, Lapchak PH, Rani P, Pine P, Dalle Luca JJ, Tsokos GC. Spleen tyrosine kinase inhibition prevents tissue damage after ischemia-reperfusion. Am J Physiol Gastrointest Liver Physiol 2010, 299:G391-399. 10.1152/ajpgi.00198.2010, 20522642.
58. Gross O, Poeck H, Bscheider M, Dostert C, Hannesshlager N, Endres S, Hartmann G, Tardivel A, Schweighoffer E, Tybulewicz V, Mocsai A, Tschopp J. Syk kinase signaling couples to the Nlpr3 inflammasome for anti-fungal host defence. Nature 2009, 459:433-436. 10.1038/nature07965, 19339971.
59. Poeck H, Ruland J. Syk kinase signaling and the Nlpr3 inflammasome in antifungal immunity. J Mol Med 2010, 88:745-752. 10.1007/s00109-010-0631-4, 20401456.
60. Shi Y, Mucsi AD, Ng G. Monosodium urate crystals in inflammation and immunity. Immunol Rev 2010, 233:203-217. 10.1111/j.0105-2896.2009.00851.x, 20193001.
61. Martinon F, Petrilli F, Mayor A, Tardivel A, Tschopp J. Gout-associated uric-acid crystals activate the NALP3 inflammasome. Nature 2006, 440:237-241. 10.1038/nature04516, 16407889.
62. Desaulniers B, Fernandes M, Gilbert C, Bourgoin SG, Naccache PH. Crystal-induced neutrophil activation. VII. Involvement of Syk in the responses to monosodium urate crystals. J Leukoc Biol 2001, 70:659-668.
63. Ruland J. CARD9 signaling in the innate immune response. Ann N Y Acad Sci 2008, 1143:35-44. 10.1196/annals.1443.024, 19076343.
64. Böhmer R, Neuhaus B, Bühren S, Zhang D, Stehling M, Böck B, Kiefer F. Regulation of developmental lymphangiogenesis by Syk(+) leukocytes. Dev Cell 2010, 18:437-449. 10.1016/j.devcel.2010.01.009, 20230750.